Ask about this productRelated genes to: CKMM protein
- Gene:
- CKM NIH gene
- Name:
- creatine kinase, M-type
- Previous symbol:
- CKMM
- Synonyms:
- -
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-02-10
Related products to: CKMM protein
Related articles to: CKMM protein
- Cardiovascular-kidney-metabolic (CKM) syndrome is a recently defined clinical entity that encompasses cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic disorders. It has emerged as a growing public health concern that adversely affects the quality of life and imposes a substantial burden on human health. Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a novel class of oral hypoglycemic agent with novel insulin-independent mechanism. In the last decade, published studies highlight its substantial effects on renal and cardiovascular outcomes. SGLT-2i is recommended for patients with stages 2-4 CKM syndrome, particularly those with CKD or diabetes to delay disease progression, and improve long-term clinical outcomes. This review comprehensively summarizes the current clinical evidence and elucidates the underlying mechanisms of SGLT-2i in CKM syndrome. Glycosuria and natriuresis, the primary effects of SGLT2 inhibition, play a pivotal role in improving glycemic control, reducing body weight, and lowering blood pressure. These initial effects trigger a cascade of downstream mechanisms: hemodynamic optimization via interstitial fluid reduction, enhanced cardiac efficiency through ketogenesis, and attenuation of inflammation and oxidative stress. Additional systemic benefits include increased fatty acid utilization, reduced hyperuricemia and stimulated erythropoiesis, thereby generating a network of interrelated therapeutic benefits in CKM syndrome. The pleiotropic effects of SGLT-2i position it as a highly promising therapeutic strategy for CKM syndrome. A deeper understanding of underlying mechanisms will better inform the application of SGLT-2i for this newly defined condition and guide optimal treatment strategies. - Source: PubMed
Publication date: 2026/04/10
Yang YanZhou WenYang MinTang Sydney C WLiu Bi-Cheng - Cardiovascular-kidney-metabolic (CKM) syndrome is a recently proposed framework emphasizing the interconnected nature of cardiovascular, kidney, and metabolic disorders. These conditions share risk factors with cancer, but the relationship between CKM stage and cancer risk remains unclear. We aimed to investigate a longitudinal association in a large-scale, nationwide population. - Source: PubMed
Publication date: 2026/04/27
Azegami TatsuhikoKaneko HidehiroSuzuki YutaOkada AkiraKo ToshiyukiJimba TakahiroEjiri KentaroMizuno AtsushiFujiu KatsuhitoTakeda NorifumiMorita HiroyukiYuasa ShinsukeNode KoichiNangaku MasaomiTakeda NorihikoYasunaga HideoHayashi Kaori - - Source: PubMed
Publication date: 2026/04/27
Bell Caitlin F - Cardiovascular-kidney-metabolic (CKM) syndrome is an emerging clinical entity that highlights the complex, bidirectional interplay among cardiovascular disease, chronic kidney disease, and metabolic disorders, representing a substantial and growing global health burden. This conceptualization marks a paradigm shift from viewing these conditions in isolation to understanding them as an interconnected disease continuum. Traditional biomarkers face significant limitations in the early detection, risk stratification, and precise management of CKM, necessitating a transition towards an integrated framework that captures its multisystem nature. This review systematically outlines an emerging multidimensional biomarker system encompassing key pathological axes such as metabolism, immuno-inflammation, oxidative stress, and biological aging, offering refined risk assessment beyond conventional metrics. The development of this system is propelled by revolutionary platforms, including accessible sampling techniques (e.g., dried blood spots), advanced in vitro models (e.g., multi-organ-on-a-chip), and multi-omics technologies. These platforms not only facilitate a deeper dissection of the heterogeneous origins and inter-organ crosstalk in CKM but also accelerate the discovery and validation of novel biomarkers. Concurrently, artificial intelligence serves as a pivotal tool for clinical translation, effectively integrating high-dimensional data to transform complex molecular profiles into actionable clinical insights. By enabling the construction of dynamic risk prediction and decision-support systems, this review charts a pathway toward proactive, individualized, and precise prevention and management of CKM syndrome. - Source: PubMed
Publication date: 2026/04/26
Li Fei-HongLi Yuan-YuZhang YueYang LiuPan Shao-KangLiu Dong-WeiLiu Zhang-SuoGao Zhong-XiuziWu Peng - We critically appraise a large prospective cohort study on left atrial enlargement and 1-year cerebrovascular events in patients without atrial fibrillation. While the study provides valuable short-term prognostic evidence, we highlight four key considerations: the overlooked impact of cardiovascular-kidney-metabolic interaction, cautious interpretation of sex-specific findings due to lacking formal interaction tests, potential indication bias in antiplatelet protection claims, and the value of additional atrial cardiomyopathy markers beyond left atrial volume index. Addressing these aspects would enhance risk stratification and translational applicability. - Source: PubMed
Publication date: 2026/04/24
Dong WeikaiYang GuangminWang Qiang